Our data showed that knockdown of PELI1 enhanced the sensitivity of EGFR inhibitor against the EMT in breast cancer cells through a decrease of EGFR levels, suggesting that co-inhibition of PELI1 and EGFR have a synergetic effect with EGFR-TKI. Here, PELI1 is linked to breast carcinoma.